How high-density lipoprotein protects against the effects of lipid peroxidation

Current Opinion in Lipidology

Volumn 11, Issue 4, 2000, Pages 383-388

  Mackness, Michael I ^a   Durrington, Paul N ^a   Mackness, Bharti ^a  

^a MANCHESTER ROYAL INFIRMARY   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ENZYME; HIGH DENSITY LIPOPROTEIN; LIPID; LIPID PEROXIDE; LOW DENSITY LIPOPROTEIN; PON 1; UNCLASSIFIED DRUG;

ATHEROSCLEROSIS; CLINICAL TRIAL; ENZYME ACTIVITY; HUMAN; HYDROLYSIS; LIPID PEROXIDATION; MOUSE; NONHUMAN; PRIORITY JOURNAL; RAT; REVIEW;

ANIMALS; ARTERIOSCLEROSIS; ARYLDIALKYLPHOSPHATASE; CORONARY DISEASE; ENDOTHELIUM; ESTERASES; HUMANS; LIPID PEROXIDATION; LIPOPROTEINS, HDL; LIPOPROTEINS, LDL; MICE; MONOCYTES; PHOSPHATIDYLCHOLINES; POLYMORPHISM, GENETIC; STEROL O-ACYLTRANSFERASE;

EID: 0033860421     PISSN: 09579672     EISSN: None     Source Type: Journal    
DOI: 10.1097/00041433-200008000-00007     Document Type: Review

References (63)

1. 1 Miller GJ, Miller NE. Plasma high-density lipoprotein concentration and the development of ischaemic heart disease. Lancet 1975; i:16-19.
2. 2 Castelli WP, Garrison RJ, Wilson PW, et al. Incidence of coronary heart disease and lipoprotein cholesterol levels. The Framingham Study. JAMA 1986; 256:2835-2838.
3. 3 Consensus Statement. Triglyceride, high-density lipoprotein and coronary heart disease. 1992; 10:1-28.
4. 4 Assmann G, Schulte H, von Eckardstein A, Huang Y. High density lipoprotein cholesterol as a predictor of coronary heart disease risk. The PROCAM experience and pathophysiological implications for reverse cholesterol transport. Atherosclerosis 1996; 124:S11-S20.
5. 5 Tanne D, Yaari S, Goldbourt U. High-density lipoprotein cholesterol and risk of ischaemic stroke mortality. A 21 year follow-up of 8586 men from the Israeli Ischaemic Heart Disease Study. Stroke 1997; 21:83-87.
6. 6 Benoit P, Emmanuel F, Caillund JM, et al. Somatic gene transfer of human apo A1 inhibits atherosclerosis progression in mouse models. Circulation 1999; 99:105-110. See 8•• below.
7. 7 Tangirala RK, Tsukamoto K, Chun SH, et al. Regression of atherosclerosis induced by liver-directed gene transfer of apolipoprotein AI in mice. Circulation 1999; 100:1816-1822. See 8•• below.
8. 8 Dansky HM, Charlton SA, Barlow CB, et al. Apo AI inhibits foam cell formation in apo E-deficient mice after monocyte adherence to the endothelium. J Clin Invest 1999; 104:31-39. The above three references are important in providing evidence that gene transfer of human apolipoprotein A1 into atherosclerosis-susceptible animal models increases HDL concentrations and inhibits atherosclerosis.
9. 9 Mackness MI, Mackness B. HDL: are there any benefits to raising it? In: Current perspectives in lipidology. Bettridge DJ (editor). London: Martin Dunitz Publishers; 2000. in press.
10. 10 Steinberg D, Parthasarathy S, Carew TE, et al. Beyond cholesterol modifications of low-density lipoprotein that increase its atherogenicity. N Engl J Med 1989; 320:915-924.
11. 11 Parthasarathy S, Santanam N, Auge N. Oxidised low-density lipoprotein: a two-faced Janus in coronary artery disease? Biochem Pharmacol 1998; 56:279-284.
12. 12 Parthasarathy S, Santanam N, Ramachandran S, Meilhac O. Oxidants and antioxidants in atherogenesis: an appraisal. J Lipid Res 1999; 40:21143-2157.
13. 13 McIntyre TM, Zimmerman GA, Prescott SM. Biologically active oxidised phospholipids. J Biol Chem 1999; 274:25189-25192.
14. 14 Subbanagounder G, Leitinger N, Shih PT, et al. Evidence that phospholipid oxidation products and/or platelet-activating factor play an important role in early atherogenesis. Circ Res 1999; 85:311-318. Important evidence as to the lipid molecular species of oxidized LDL that are able to cause endothelial activation in the early stages of atherogenesis.
15. 15 Parthasarathy S, Barnett J, Fong LG. High-density lipoprotein inhibits the oxidative modification of low-density lipoprotein. Biochim Biophys Acta 1990; 1044:275-283.
16. 16 Bowry VW, Stanley KK, Stocker R. High density lipoprotein is the major carrier of lipid hydroperoxides in human blood plasma from fasting donors. Proc Natl Acad Sci USA 1992; 89:10316-10320.
17. 17 Sattler W, Stocker R. Greater selective uptake by Hep G2 cells of high density lipoprotein cholesterylester hydroperoxides than unoxidised cholesterylesters. Biochem J 1993; 294:771-776.
18. 18 Christison J, Karjalaineu A, Brauman J, et al. Rapid reduction and removal of HDL but not LDL-associated cholesterylester hydroperoxides by rat liver perfused in situ. Biochem J 1996; 314:737-742.
19. 19 Klimov AN, Nikiforova AA, Kuzmin AA, et al. Is high density lipoprotein a scavenger for oxidised phospholipids of low density lipoprotein? Advances in Lipoprotein and Atherosclerosis Research, Diagnostics and Treatment. Jena: Gustav Fischer Verlag; 1998. pp. 78-82.
20. 20 Nagata Y, Yamamoto Y, Niki E. Reaction of phosphatidylcholine hydroperoxide in human plasma: the role of peroxidase and lecithin : cholesterol acyltransferase. Arch Biochem Biophys 1996; 329:24-36.
21. 21 Bhatnagar D, Durrington PN, Kumar S, et al. Plasma lipoprotein composition and cholesteryl ester transfer from high density lipoproteins to very low density and low density lipoproteins in patients with non-insulin dependent diabetes mellitus. Diabetic Med 1992; 13:139-144.
22. 22 Arrol S, Mackness MI, Durrington PN. Vitamin E supplementation increases the resistance of both LDL and HDL to oxidation and increases cholesteryl ester transfer activity. Atherosclerosis 2000; in press.
23. 23 Itabe H, Hosoga R, Karasawa K, et al. Metabolism of oxidised phosphatidylcholines formed in oxidised low density lipoprotein by lecithin : cholesterol acyltransferase. J Biochem 1999; 126:153-161.
24. 24 Subramaniam VS, Goyal J, Miwa M, et al. Role of lecithin : cholesterol acyltransferase in the metabolism of oxidised phospholipids in plasma: studies with platelet-activating factor-acetylhydrolase deficient plasma. Biochim Biophys Acta 1999; 1439:95-109.
25. 25 Vohl M-C, Neville TA-M, Kumarathasan R, et al. A novel lecithin-cholesterol acyltransferase antioxidant activity prevents the formation of oxidised lipids during lipoprotein oxidation. Biochemistry 1999; 32:5976-5981.
26. 26 Mackness MI, Abbott CA, Arrol S, Durrington PN. The role of high density lipoprotein and lipid-soluble antioxidant vitamins in inhibiting low-density lipoprotein oxidation. Biochem J 1993; 294:829-835.
27. 27 Mackness MI, Arrol S, Durrington PN. Paraoxonase prevents accumulation of lipoperoxides in low-density lipoprotein. FEBS Lett 1991; 286:152-154.
28. 28 Mackness MI, Arrol S, Abbott CA, Durrington PN. Protection of low-density lipoprotein against oxidative modification by high-density lipoprotein associated paraoxonase. Atherosclerosis 1993; 104:129-135.
29. 29 Watson AD, Berliner JA, Hama SY, et al. Protective effect of high density lipoprotein associated paraoxonase-inhibition of the biological activity of minimally oxidised low-density lipoprotein. J Clin Invest 1995; 96:2882-2891.
30. 30 Aviram M, Billecke S, Sorenson R, et al. Paraoxonase active site required for protection against LDL oxidation involves its free sulphydryl group and is different from that required for its arylesterase/paraoxonase activities: selective active of human paraoxonase alloenzymes Q and R. Arterioscler Thromb Vasc Biol 1998; 10:1617-1624.
31. 31 Shih DM, Gu L, Xia Y-R, et al. Mice lacking serum paraoxonase are susceptible to organophosphate toxicity and atherosclerosis. Nature 1998; 394:284-287.
32. 32 La Du BN. Human serum paraoxonase/arylesterase. In: Pharmacogenetics of drug metabolism. Kalow W (editor). New York: Pergamon Press; 1992. pp. 51-91.
33. 33 Davies HG, Richter RJ, Keifer M, et al. The effect of the human serum paraoxonase polymorphism is reversed with diazoxon, soman and sarin. Nature Genet 1996; 14:334-336.
34. 34 Blatter-Garin M-C, James RW, Dussoix P, et al. Paraoxonase polymorphism Met-Leu 54 is associated with modified serum concentrations of the enzyme. J Clin Invest 1997; 99:62-66.
35. 35 Mackness B, Mackness MI, Arrol S, et al. Effect of the molecular polymorphisms of human paraoxonase (PON1) on the rate of hydrolysis of paraoxon. Br J Pharmacol 1997; 112:265-268.
36. 36 Mackness MI, Arrol S, Mackness B, Durrington PN. The alloenzymes of paraoxonase determine the effectiveness of high-density lipoprotein in protecting low density lipoprotein against lipid-peroxidation. Lancet 1997; 349:851-852.
37. 37 Mackness B, Mackness MI, Arrol S, et al. Effect of the human serum paraoxonase 55 and 192 genetic polymorphisms on the protection by high density lipoprotein against low density lipoprotein oxidative modification. FEBS Lett 1998; 423:57-60.
38. 38 Mackness B, Durrington PN, Mackness MI. Polymorphisms of paraoxonase genes and low-density lipoprotein lipid peroxidation. Lancet 1999; 353:468-469.
39. 39 Mackness MI, Mackness B, Durrington PN, et al. Paraoxonase and coronary heart disease. Curr Opin Lipidol 1998; 9:319-324.
40. 40 Hasselwander O, Savage DA, McMaster D, et al. Paraoxonase polymorphisms are not associated with cardiovascular risk in renal transplant recipients. Kidney Int 1999; 56:289-298.
41. 41 Pfohl M, Koch M, Enderle MD, et al. Paraoxonase 192 Gln/Arg gene polymorphism, coronary artery disease, and myocardial infarction in type 2 diabetes. Diabetes 1999; 48:623-627.
42. 42 Salonen JT, Malin R, Toumaineu T-P, et al. Polymorphism in high density lipoprotein gene and risk of acute myocardial infarction in men: prospective nested case-control study. BMJ 1999; 319:487-488. The data in this manuscript have led to the claim that the PON1-55 polymorphism accounts for 20% of all infarcts, a rather exaggerated claim.
43. 43 Cascorbi I, Laule M, Mrozikiewicz PM, et al. Mutations in the human PON1 gene: frequencies, allelic linkages and association with coronary artery disease. Pharmacogenetics 1999; 9:755-761.
44. 44 Aubó C, Sentí M, Marrugat J, et al. Risk of myocardial infarction associated with diabetes mellitus. Eur Heart J 2000; 21:33-38.
45. 45 Ayub A, Mackness MI, Arrol S, et al. Serum paraoxonase after myocardial infarction. Arterioscler Thromb Vasc Biol 1999; 19:330-335. See 47•• below.
46. 46 Mackness B, Mackness MI, Durrington PN, et al. Paraoxonase activity in two healthy populations with differing rates of coronary heart disease. Eur J Clin Invest 2000; 30:4-10. See 47•• below.
47. 47 Richter RJ, Furlong CE. Determination of paraoxonase (PON1) status requires more than genotyping. Pharmacogenetics 1999; 9:745-753. The above three manuscripts illustrate the cogent need to add a measurement of the PON1 enzyme to genotyping data to provide sensible information in future studies.
48. 48 Akhmedova S, Anisimov S, Yakimovsky A, Schwartz E. Gln→Arg 191 polymorphism of paraoxonase and Parkinson's Disease. Hum Hered 1999; 49:178-180. See 50•• below.
49. 49 Malin R, Rantalaiho V, Huang X-H, et al. Association between M/L55-polymorphism of paraoxonase enzyme and oxidative DNA damage in patients with type 2 diabetes mellitus and in control subjects. Hum Genet 1999; 105:179-180. See 50•• below.
50. 50 Mackness B, Durrington PN, Abuashia B, et al. Low paraoxonase activity in type II diabetes complicated by retinopathy. Clin Sci 2000; 98:355-363. The above three manuscripts provide evidence that PON1 may play a wider role in the prevention of lipid peroxidation and that its action may not be restricted to atherosclerosis.
51. 51 Stafforini DM, Zimmerman GA, McIntyre TM, Prescott SM. The platelet-activating factor acetylhydrolase from human plasma prevents oxidative modification of low density lipoprotein. Trans Assoc Am Phys 1993; 10:44-63.
52. 52 Watson AD, Navab M, Hama SY, et al. Effect of platelet-activating factor-acetylhydrolase on the formation and action of minimally oxidised low-density lipoprotein. J Clin Invest 1995; 95:774-782.
53. 53 Lee C, Sigari F, Segrado T, et al. All apo-B containing lipoproteins induce monocyte chemotaxis and adhesion when minimally modified-modulation of lipoprotein bioactivity by platelet-activating factor acetylhydrolase. Arterioscler Thromb Vasc Biol 1999; 19:1437-1446.
54. 54 Macphee C, Moores KE, Boyd HF, et al. Lipoprotein-associated phospholipase A2, platelet-activating factor acetylhydrolase, generates two bioactive products during the oxidation of low-density lipoprotein: use of a novel inhibitor. Biochem J 1999; 338:479-487. An alternative to the mainstream view that PAF-AH is anti-inflammatory and anti-atherogenic. This manuscript suggests a pro-atherogenic role of PAF-AH, a theory that deserves further investigation.
55. 2, platelet-activating factor acetylhydrolase, is expressed by macrophages in human and rabbit atherosclerotic lesions. Arterioscler Thromb Vasc Biol 1999; 19:2909-2917.
56. 56 Aviram M, Rosenblat M, Bisgaier CL, et al. Paraoxonase inhibits high-density lipoprotein and preserves its functions. J Clin Invest 1998; 101:1581-1590.
57. 57 Mackness MI, Durrington PN. High density lipoprotein, its enzymes and its potential to influence lipid peroxidation. Atherosclerosis 1995; 115:243-253.
58. 58 Shih DM, Gu L, Hama S, et al. Genetic-dietary regulation of serum paraoxonase expression and its role in atherogenesis in a mouse model. J Clin Invest 1996; 97:1630-1639.
59. 59 Mackness M, Bouiller A, Hennuyer N, et al. Paraoxonase activity is reduced by a pro-atherosclerotic diet in rabbits. Biochem Biophys Res Commun 2000; in press.
60. 60 Aviram M, Rosenblat M, Billecke S, et al. Human serum paraoxonase (PON1) is inactivated by oxidised low density lipoprotein and preserved by antioxidants. Free Rad Biol Med 1999; 26:892-904. This manuscript provides the first basic information on the interaction between human PON1, oxidized LDL and naturally occurring antioxidants. The data, if confirmed, have important implications for the action and modulation of PON1 activity.
61. 61 Aviram M. Does paraoxonase play a role in susceptibility to cardiovascular disease? Mol Med Today 1999; 5:381-386.
62. 62 van der Gaag MS, van Tol A, Scheek LM, et al. Daily moderate alcohol consumption increases serum paraoxonase activity; a diet-controlled, randomised intervention study in middle-aged men. Atherosclerosis 1999; 147:405-410. See 63•• below.
63. 63 Sutherland WHF, Walker RJ, de Jong SA, et al. Reduced postprandial serum paraoxonase activity after a meal rich in used cooking fat. Arterioscler Thromb Vasc Biol 1999; 19:1340-1347. These publications have provided the first case-control studies showing that dietary modulation of PON1 can occur in humans. Previously this had only been suspected from differences between relatively homogeneous populations.